ABC Arbitrage SA Trims Stock Position in Haleon PLC Sponsored ADR $HLN

ABC Arbitrage SA decreased its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 82.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 477,377 shares of the company’s stock after selling 2,312,074 shares during the quarter. ABC Arbitrage SA’s holdings in Haleon were worth $4,779,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Haleon in the fourth quarter valued at approximately $163,529,000. Natixis Advisors LLC grew its position in shares of Haleon by 429.8% during the fourth quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock worth $101,140,000 after acquiring an additional 8,115,633 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Haleon by 4,315.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock valued at $81,155,000 after acquiring an additional 7,845,391 shares during the period. Bank of Montreal Can increased its holdings in shares of Haleon by 454.1% in the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock valued at $85,940,000 after acquiring an additional 6,966,416 shares during the period. Finally, Bank of America Corp DE raised its position in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

Shares of NYSE HLN opened at $9.87 on Tuesday. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average price is $9.21 and its 200 day moving average price is $9.86. Haleon PLC Sponsored ADR has a 52 week low of $8.65 and a 52 week high of $11.28. The stock has a market cap of $43.45 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 2.26 and a beta of 0.13.

Wall Street Analyst Weigh In

HLN has been the subject of a number of recent research reports. Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Sunday. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.